AskGene Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AskGene Pharma, Inc. - overview
Established
2012
Location
Camarillo, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2012, AskGene Pharma, Inc. operates as a clinical-stage biopharmaceutical company that develops a biological drug for oncology and autoimmune disease treatment. In May 2022, AskGene Pharma, Inc. raised USD 20 million in a Series A funding co-led by Qiming Venture Partners and TF Capital.
As of May 2022, Jeff Lu is the CEO of AskGene Pharma, Inc. The product line of AskGene Pharma includes cytokine prodrugs and antibodies that target the immune cells of a wide range of digestive tract cancers, such as gastric, pancreatic, esophageal, and liver cancers. The company is also developing cytokine fusion molecules for the treatment of inflammatory disorders and autoimmune diseases. In addition, the firm is also developing ASKG712 to address specific needs in ophthalmology, including diabetic macular edema (DME), and wet age-related macular degeneration (wAMD).
AskGene uses SmartKine platform to develop these novel biological drugs. The company plans to use its proceeds from May 2022 funding for the development of its SmartKine cytokine prodrug platform and advance the clinical development of its therapeutic candidates.
Current Investors
Qiming Venture Partners, TF Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.ask-gene.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.